
|Articles|September 7, 2016
How Many Opioids Have Received ADP Designation on the Basis of Category 1 Studies Alone?
J. David Haddox, DDS, MD, corrects a misconception about opioids with abuse-deterrent properties.
Advertisement
J. David Haddox, DDS, MD, corrects a misconception about opioids with abuse-deterrent properties.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
FDA Approves Lerodalcibep for Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
5

















































































































































































































